Accuray - ARAY Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARAY shares.
View ARAY analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12 month target prices for Accuray's shares. Their ARAY share price forecasts range from $7.00 to $7.50. On average, they predict the company's stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 252.6% from the stock's current price.
View analysts price targets for ARAY or view top-rated stocks among Wall Street analysts.

Accuray's stock was trading at $4.77 at the beginning of 2022. Since then, ARAY stock has decreased by 56.4% and is now trading at $2.08.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ARAY earnings forecast.

Accuray Incorporated (NASDAQ:ARAY) posted its quarterly earnings data on Wednesday, August, 10th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. Accuray had a negative net margin of 1.24% and a negative trailing twelve-month return on equity of 10.61%. During the same quarter in the previous year, the business posted ($0.01) EPS.

Accuray issued an update on its FY 2023 earnings guidance on Friday, September, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $447.00 million-$455.00 million, compared to the consensus revenue estimate of $425.20 million.

107 employees have rated Accuray Chief Executive Officer Joshua Levine on Glassdoor.com. Joshua Levine has an approval rating of 45% among the company's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 75.0% of employees surveyed would recommend working at Accuray to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Accuray's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.96%), Royce & Associates LP (2.85%), Assenagon Asset Management S.A. (1.78%), Millennium Management LLC (1.20%), State Street Corp (0.86%) and Lapides Asset Management LLC (0.85%). Insiders that own company stock include Andrew J Kirkpatrick, Brandon W Green, Byron C Scott, Jesse Chew, Joseph E Whitters, Joshua Levine, Michael Hoge, Patrick Spine, Shigeyuki Hamamatsu and Suzanne C Winter.
View institutional ownership trends.

Shares of ARAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARAY stock can currently be purchased for approximately $2.08.

Accuray (NASDAQ:ARAY) has a market capitalization of $194.48 million and generates $429.91 million in revenue each year. The medical equipment provider earns $-5,350,000.00 in net income (profit) each year or ($0.06) on an earnings per share basis.

The company employs 1,044 workers across the globe.

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The official website for the company is www.accuray.com. The medical equipment provider can be reached via phone at (408) 716-4600, via email at mpolyviou@evcgroup.com, or via fax at 408-716-4601.